4.8 Article

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Journal

SCIENCE
Volume 362, Issue 6414, Pages 558-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aat0572

Keywords

-

Funding

  1. NIH [R01HL082945, P01CA108631]
  2. Howard Hughes Medical Institute
  3. Edward P. Evans Foundation
  4. Leukemia and Lymphoma Society
  5. European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program [666068]
  6. National Institute of General Medical Sciences [T32GM007753]
  7. Human Frontier Science Program (HFSP Long-Term Fellowship) [LT000210/2014]
  8. European Molecular Biology Organization (EMBO Advanced Fellowship) [aALTF 761-2016]
  9. European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant [702642]
  10. National Health and Medical Research Council [APP1124979]
  11. Marie Curie Actions (MSCA) [702642] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys(2)-His(2) (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4(CRBN) E3 ubiquitin ligase. We screened the human C2H2 zinc finger proteome for degradation in the presence of thalidomide analogs, identifying 11 zinc finger degrons. Structural and functional characterization of the C2H2 zinc finger degrons demonstrates how diverse zinc finger domains bind the permissive drug-CRBN interface. Computational zinc finger docking and biochemical analysis predict that more than 150 zinc fingers bind the drug-CRBN complex in vitro, and we show that selective zinc finger degradation can be achieved through compound modifications. Our results provide a rationale for therapeutically targeting transcription factors that were previously considered undruggable.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available